These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 37889309)
1. Construction of cuproptosis signature based on bioinformatics and experimental validation in clear cell renal cell carcinoma. Tian X; Zhu S; Liu W; Wu X; Wei G; Zhang J; Anwaier A; Chen C; Ye S; Che X; Xu W; Qu Y; Zhang H; Ye D J Cancer Res Clin Oncol; 2023 Dec; 149(19):17451-17466. PubMed ID: 37889309 [TBL] [Abstract][Full Text] [Related]
2. A Novel Cuproptosis-Related Prognostic Gene Signature and Validation of Differential Expression in Clear Cell Renal Cell Carcinoma. Bian Z; Fan R; Xie L Genes (Basel); 2022 May; 13(5):. PubMed ID: 35627236 [TBL] [Abstract][Full Text] [Related]
3. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma. Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201 [TBL] [Abstract][Full Text] [Related]
4. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer. Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X Front Immunol; 2022; 13():1056932. PubMed ID: 36479114 [TBL] [Abstract][Full Text] [Related]
5. Pan-cancer analysis of cuproptosis regulation patterns and identification of mTOR-target responder in clear cell renal cell carcinoma. Long S; Wang Y; Chen Y; Fang T; Yao Y; Fu K Biol Direct; 2022 Oct; 17(1):28. PubMed ID: 36209249 [TBL] [Abstract][Full Text] [Related]
6. Development and validation of a novel 5 cuproptosis-related long noncoding RNA signature to predict diagnosis, prognosis, and drug therapy in clear cell renal cell carcinoma. Chen Y; Hu W; Wei X; Zhang L; Shao Y; Tian J; Wang D; Wu B Transl Androl Urol; 2023 Apr; 12(4):622-641. PubMed ID: 37181235 [TBL] [Abstract][Full Text] [Related]
7. Bioinformatics analysis and experimental validation of cuproptosis-related lncRNA LINC02154 in clear cell renal cell carcinoma. Shen J; Wang L; Bi J BMC Cancer; 2023 Feb; 23(1):160. PubMed ID: 36797708 [TBL] [Abstract][Full Text] [Related]
8. Cuproptosis-Related 4-Gene Risk Model for Predicting Immunotherapy Drug Response and Prognosis of Kidney Renal Clear Cell Carcinoma. Guo JS; Ding H; Wu PY; Xin ZY; Li JX; Jo HS; Ma ZH Chin Med Sci J; 2023 Sep; 38(3):191-205. PubMed ID: 37503721 [TBL] [Abstract][Full Text] [Related]
9. A Cuproptosis-Related lncRNAs Signature Could Accurately Predict Prognosis in Patients with Clear Cell Renal Cell Carcinoma. Zhang W; Wang H; Wang W; Xue H; Qiao M; Song L; Wang S; Ren Z; Ma Z Anal Cell Pathol (Amst); 2022; 2022():4673514. PubMed ID: 36588797 [TBL] [Abstract][Full Text] [Related]
10. Cuproptosis-related gene Huang S; Cai C; Zhou K; Wang X; Wang X; Cen D; Weng G Aging (Albany NY); 2023 Nov; 15(21):12314-12329. PubMed ID: 37938155 [TBL] [Abstract][Full Text] [Related]
11. The cuproptosis related genes signature predicts the prognosis and correlates with the immune status of clear cell renal cell carcinoma. Sun P; Xu H; Zhu K; Li M; Han R; Shen J; Xia X; Chen X; Fei G; Zhou S; Wang R Front Genet; 2022; 13():1061382. PubMed ID: 36531222 [No Abstract] [Full Text] [Related]
12. Comprehensive investigation into cuproptosis in the characterization of clinical features, molecular characteristics, and immune situations of clear cell renal cell carcinoma. Wang B; Song Q; Wei Y; Wu X; Han T; Bu H; Tang S; Qian J; Shao P Front Immunol; 2022; 13():948042. PubMed ID: 36275737 [TBL] [Abstract][Full Text] [Related]
13. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma. Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062 [TBL] [Abstract][Full Text] [Related]
14. Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma. Cai Z; He Y; Yu Z; Hu J; Xiao Z; Zu X; Li Z; Li H Front Immunol; 2022; 13():933241. PubMed ID: 36211378 [TBL] [Abstract][Full Text] [Related]
15. Integrated single-cell and bulk characterization of cuproptosis key regulator PDHB and association with tumor microenvironment infiltration in clear cell renal cell carcinoma. Wu J; Wang S; Liu Y; Zhang T; Wang X; Miao C Front Immunol; 2023; 14():1132661. PubMed ID: 37350959 [TBL] [Abstract][Full Text] [Related]
16. Cuproptosis-related molecular patterns and gene (ATP7A) in hepatocellular carcinoma and their relationships with tumor immune microenvironment and clinical features. Li S; Weng J; Xiao C; Lu J; Cao W; Song F; He Z; Zhang P; Zhu Z; Xu J Cancer Rep (Hoboken); 2023 Dec; 6(12):e1904. PubMed ID: 37885090 [TBL] [Abstract][Full Text] [Related]
17. Exploring the prognostic implications of cuproptosis-associated alterations in clear cell renal cell carcinoma via in vitro experiments. Xing Z; Cui L; Feng Y; Yang Y; He X Sci Rep; 2024 Jul; 14(1):16935. PubMed ID: 39043799 [TBL] [Abstract][Full Text] [Related]
18. Cuproptosis related gene PDHB is identified as a biomarker inversely associated with the progression of clear cell renal cell carcinoma. Wang H; Yang Z; He X; Guo F; Sun H; Xu S; Xu C; Wang Z; Wen H; Teng Z; Wang Y; Han Z BMC Cancer; 2023 Aug; 23(1):804. PubMed ID: 37641032 [TBL] [Abstract][Full Text] [Related]
19. Identification and Validation of Cuproptosis-Related LncRNA Signatures in the Prognosis and Immunotherapy of Clear Cell Renal Cell Carcinoma Using Machine Learning. Bai Z; Lu J; Chen A; Zheng X; Wu M; Tan Z; Xie J Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551318 [TBL] [Abstract][Full Text] [Related]
20. A novel cuproptosis-related prognostic gene signature and validation of differential expression in hepatocellular carcinoma. Li Y; Zeng X Front Pharmacol; 2022; 13():1081952. PubMed ID: 36703728 [No Abstract] [Full Text] [Related] [Next] [New Search]